Borgeson Blake has recently reported a significant stock transaction involving Recursion Pharmaceuticals. The filing reveals that Borgeson Blake sold 50,000 shares of Recursion Pharmaceuticals at a weighted average price of $4.84 each. This transaction took place on October 6, 2026, and was disclosed in a Form 4 filing with the SEC.
This sale is notable as it reflects insider trading activity within the biotechnology sector, which often serves as an indicator of confidence or concern regarding a company's future performance. The biotechnology industry is characterized by rapid developments and can be sensitive to insider movements, making such transactions worthy of attention.
Background
Borgeson Blake is an entity associated with Recursion Pharmaceuticals, Inc., which operates in the biological products sector. Recursion Pharmaceuticals is known for its innovative approaches in drug discovery and development. The company is based in Salt Lake City, Utah, and is publicly traded under the ticker symbol RXRX.
What the Filing Says
The recent filing indicates that Borgeson Blake disposed of 50,000 shares of Class A Common Stock. The transaction was executed under a Rule 10b5-1 trading plan that Borgeson Blake adopted on August 31, 2025. Following this transaction, Borgeson Blake holds a total of 6,108,287 shares of Recursion Pharmaceuticals.
Impact
This sale may affect various stakeholders, including other shareholders, potential investors, and market analysts. Insider transactions can influence market perceptions and investor confidence, particularly in the biotechnology sector where developments can rapidly change a company's outlook.
What's Next
The filing does not say what happens next.